Swedish Medical Center

Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis (2024) Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S, Seridi L, et al. Journal article Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis (2024) Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, Cua DJ, et al. Journal article Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast (2022) Mease PJ, Gladman D, Schett G, Paris M, Cheng S, Richter S, Teng L, Kavanaugh A Conference contribution GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY (2022) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Cua D, et al. Conference contribution IMMUNOLOGICAL DIFFERENCES BETWEEN PSA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS (2022) Siebert S, Coates L, Schett G, Raychaudhuri SP, Chen W, Gao S, Chakravarty SD, et al. Conference contribution Guselkumab (TREMFYA (R)) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study (2021) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease P, Shawi M, Cua D, et al. Conference contribution Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study (2021) Mease P, Deodhar A, Merola J, Mcinnes I, Assudani D, Bajracharya R, Coarse J, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials (2021) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, et al. Journal article Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. (2021) Mcgonagle D, Mcinnes IB, Deodhar A, Schett G, Shawi M, Kafka S, Karyekar CS, et al. Journal article Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials (2020) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Journal article